{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Daré Bioscience, Inc.
Is Daré Bioscience, Inc. overvalued or undervalued?
As of May 13, 2025, Daré Bioscience, Inc. is considered overvalued with negative financial metrics and a valuation grade of "does not qualify," significantly underperforming compared to peers and the S&P 500.
Is Daré Bioscience, Inc. technically bullish or bearish?
As of December 30, 2024, the market trend is mildly bearish, with mixed indicators showing some bullish signals but prevailing bearish conditions suggesting caution.
Who are in the management team of Daré Bioscience, Inc.?
As of March 2022, the management team of Daré Bioscience, Inc. is led by Dr. William Rastetter (Independent Chairman) and Ms. Sabrina Johnson (President and CEO), supported by several independent directors including Dr. Cheryl Blanchard, Ms. Jessica Grossman, Mr. Steve Hall, Dr. Susan Kelley, and Mr. Gregory Matz.
What does Daré Bioscience, Inc. do?
Daré Bioscience, Inc. is a micro-cap healthcare company focused on developing and commercializing products for women’s reproductive health. As of March 2025, it reported net sales of $0 million and a net loss of $4 million, with a market cap of $25.53 million.
How big is Daré Bioscience, Inc.?
As of Jun 18, Daré Bioscience, Inc. has a market capitalization of 25.53 million and reported net sales of 0.10 million with a net profit of -2.93 million over the latest four quarters. Shareholder's funds are at -6.01 million, and total assets amount to 22.10 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
